Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban

PHASE4UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2017

Conditions
Atrial FibrillationStroke
Interventions
DEVICE

WATCHMAN Left Atrial Appendage Occlusion Device

DRUG

Rivaroxaban

Trial Locations (9)

100029

Beijing Anzhen Hospital, Beijing

430000

Wuhan Asia Heart Hospital, Wuhan

510000

Nanfang Hospital, Guangzhou

The first Affiliated Hospital of Guangzhou medical University, Guangzhou

The first affiliated hospital of Jinan university, Guangzhou

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

The second Affiliated Hospital of Guangzhou medical University, Guangzhou

510080

Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangzhou

524000

The Affiliated Hospital of Guangdong Medical College, Zhanjiang

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Wuhan Asia Heart Hospital

OTHER

collaborator

Beijing Anzhen Hospital

OTHER

collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Second Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Guangdong Medical College

OTHER

collaborator

First Affiliated Hospital of Jinan University

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

lead

Shulin Wu

OTHER

NCT02549963 - Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban | Biotech Hunter | Biotech Hunter